Evidence map›Paper›PMID 32914236›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2020

Measures of infection prevention and incidence of SARS-CoV-2 infections in cancer patients undergoing radiotherapy in Germany, Austria and Switzerland.

Christiane Matuschek, Johannes C Fischer, Stephanie E Combs, Rainer Fietkau, Stefanie Corradini, Kurt Zänker, Edwin Bölke, Freddy-Joel Djiepmo-Njanang, Balint Tamaskovics, Joachim E Fischer and 18 more

Open access · hybridAbstract read
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Impact of the COVID-19 pandemic on oncological care in Germany: rapid review.Journal of cancer research and clinical oncology · 2023
    Review
  2. Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  3. Shift of radiotherapy use during the first wave of the COVID-19 pandemic? An analysis of German inpatient data.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022
    Article
  4. Article
  5. Risk stratification by anamnesis increases SARS-CoV-2 test efficiency in cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 15 institutions in 5 countries.

Christiane MatuschekMedical Faculty, Department of Radiation Oncology, Heinrich Heine University, Duesseldorf, Germany.
Johannes C FischerInstitute for Transplant Diagnostics and Cell Therapeutics, Heinrich Heine University, Düsseldorf, Germany.
Stephanie E CombsDepartment of Radiation Oncology, Technical University of Munich, Munich, Germany.
Rainer FietkauDepartment of Radiation Oncology, University of Erlangen, Erlangen, Germany.
Stefanie CorradiniDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Kurt ZänkerUniversity Witten/Herdecke, Witten, Germany.
Edwin BölkeMedical Faculty, Department of Radiation Oncology, Heinrich Heine University, Duesseldorf, Germany. boelke@med.uni-duesseldorf.de.ORCID http://orcid.org/0000-0001-9112-1024
Freddy-Joel Djiepmo-NjanangMedical Faculty, Department of Radiation Oncology, Heinrich Heine University, Duesseldorf, Germany.
Balint TamaskovicsMedical Faculty, Department of Radiation Oncology, Heinrich Heine University, Duesseldorf, Germany.ORCID http://orcid.org/0000-0002-2533-0167
Joachim E FischerPublic Health, University of Mannheim, Mannheim, Germany.
Martin StuschkeDepartment of Radiation Oncology, University Essen, Essen, Germany.
Christoph PöttgenDepartment of Radiation Oncology, University Essen, Essen, Germany.
Robert FörsterInstitute of Radiation Oncology, Cantonal Hospital Winterthur, University of Zurich, Zurich, Switzerland.
Daniel R ZwahlenInstitute of Radiation Oncology, Cantonal Hospital Winterthur, University of Zurich, Zurich, Switzerland.
Alexandros PapachristofilouDepartment of Radiation Oncology, University Hospital Basel, Basel, Switzerland.
Ute GanswindtDepartment of Radiation Oncology, Medical University Innsbruck, Innsbruck, Austria.
Rainer PelkaInstitute for Applied Statistics, Unterföhring/Munich, Germany.
E Marion SchneiderDivision of Experimental Anesthesiology, University Hospital Ulm, Ulm, Germany.
Torsten FeldtDepartment of Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University, Duesseldorf, Germany.
Björn Erik Ole JensenDepartment of Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University, Duesseldorf, Germany.
Dieter HäussingerDepartment of Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University, Duesseldorf, Germany.
Wolfram Trudo KnoefelDepartment for General Visceral and Pediatric Surgery, Heinrich Heine University, Dusseldorf, Germany.
Detlef Kindgen-MillesDepartment of Intensive Care Medicine, Heinrich Heine University, Dusseldorf, Germany.
Alessia PedotoDepartment of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, USA.
Olaf GrebeDepartment for Cardiology, Rhythmology and Intensive Care Medicine, Evangelic Hospital, Dusseldorf, Germany.
Martijn van GriensvenMERLN Institute for Technology-Inspired Regenerative Medicine, Department cBITE, Maastricht University, Maastricht, The Netherlands.
Wilfried BudachMedical Faculty, Department of Radiation Oncology, Heinrich Heine University, Duesseldorf, Germany.
Jan HaussmannMedical Faculty, Department of Radiation Oncology, Heinrich Heine University, Duesseldorf, Germany.
Heinrich Heine University Düsseldorf · DEEssen University Hospital · DEUniversity of Mannheim · DEUniversity of Zurich · CHEvangelisches Krankenhaus Düsseldorf · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHelmholtz Zentrum München · DEInnsbruck Medical University · ATInstitut für Angewandte Statistik · DELMU Klinikum · DEMaastricht University · NLMemorial Sloan Kettering Cancer Center · USUniversity Hospital of Basel · CHUniversity Hospital Ulm · DEWitten/Herdecke University · DE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeCOVID-19 infection has manifested as a major threat to both patients and healthcare providers around the world. Radiation oncology institutions (ROI) deliver a major component of cancer treatment, with protocols that might span over several weeks, with the result of increasing susceptibility to COVID-19 infection and presenting with a more severe clinical course when compared with the general population. The aim of this manuscript is to investigate the impact of ROI protocols and performance on daily practice in the high-risk cancer patients during this pandemic.

methodsWe addressed the incidence of positive COVID-19 cases in both patients and health care workers (HCW), in addition to the protective measures adopted in ROIs in Germany, Austria and Switzerland using a specific questionnaire.

resultsThe results of the questionnaire showed that a noteworthy number of ROIs were able to complete treatment in SARS-CoV‑2 positive cancer patients, with only a short interruption. The ROIs reported a significant decrease in patient volume that was not impacted by the circumambient disease incidence, the type of ROI or the occurrence of positive cases. Of the ROIs 16.5% also reported infected HCWs. About half of the ROIs (50.5%) adopted a screening program for patients whereas only 23.3% also screened their HCWs. The range of protective measures included the creation of working groups, instituting home office work and protection with face masks. Regarding the therapeutic options offered, curative procedures were performed with either unchanged or moderately decreased schedules, whereas palliative or benign radiotherapy procedures were more often shortened. Most ROIs postponed or cancelled radiation treatment for benign indications (88.1%). The occurrence of SARS-CoV‑2 infections did not affect the treatment options for curative procedures. Non-university-based ROIs seemed to be more willing to change their treatment options for curative and palliative cases than university-based ROIs.

conclusionMost ROIs reported a deep impact of SARS-CoV‑2 infections on their work routine. Modification and prioritization of treatment regimens and the application of protective measures preserved a well-functioning radiation oncology service and patient care.

Indexed as

PandemicsAppointments and SchedulesAustriaCancer Care FacilitiesComorbidityCOVID-19COVID-19 TestingCross InfectionCross-Sectional StudiesGermanyHospitals, CommunityHospitals, UniversityHumansIncidenceInfection ControlMasksCOVID-19OncologyPandemicPatient careRadiation oncoloy

Identifiers

PMID32914236
PMCPMC7483062
OpenAlexW3085434993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.